With the Synthes merger in hand, a new CEO in charge, and a rejuvenated pharmaceutical business, Johnson & Johnson (JNJ)
is perhaps in the best shape it has been in in quite some time. By no
means is this a flawless story, particularly as the device business
seems to need some real work, but it looks as if the company has more
going for it than against it at this point.
Please read more here:
Mind The Margins And Devices, But Johnson & Johnson Looks Alright
No comments:
Post a Comment